CoChat

Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study

Open access
Johnson, Hans, Huang, David, Liu, Vivian, Ammouri, Mahmoud Al, Jacobs, Christopher, El-Osta, Austen · 2025 · Journal of Medical Internet Research

Published version of a preprint

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index; 25 of the 39 sources its claims cite were checked for support.

Abstract

Background: Obesity is a global public health challenge. Pharmacological interventions, such as glucagon-like peptide-1 (GLP-1) receptor agonists (eg, semaglutide) and dual GLP-1/gastric inhibitory polypeptide receptor agonists (eg, tirzepatide), have led to significant weight loss among users. Digital health platforms offering behavioral support may enhance the effectiveness of these medications. Objective: This retrospective service evaluation investigated the impact of engagement with an app-based digital weight loss program on weight loss outcomes among individuals using GLP-1 receptor agonists (semaglutide) and dual GLP-1/gastric inhibitory polypeptide receptor agonists (tirzepatide) in the United Kingdom over 5 months. Methods: Data were collected from the Voy weight loss digital health platform between February 2023 and August 2024. Participants were adults aged 18-75 years with a BMI ≥30 or ≥27.5 kg/m2 with the presence of obesity-related comorbidities who initiated a weight management program involving semaglutide or tirzepatide. Engagement was defined based on attendance at coaching sessions, frequency of app use, and regular weight tracking. Participants were categorized as “engaged” or “nonengaged” accordingly. Weight loss outcomes were assessed over a period of up to 5 months. Statistical analyses included chi-square tests, independent t tests, Kaplan-Meier survival analysis, and calculations of Cohen d for effect sizes. Results: A total of 57,975 participants were included in the analysis, with 31,407 (54.2%) classified as engaged and 26,568 (45.8%) as nonengaged. Engaged participants achieved significantly greater weight loss at each time point. At month 3, engaged participants had a mean weight loss of 9% (95% CI 9% to 9.1%) compared with 5.9% (95% CI 5.9% to 6%) in nonengaged participants (P<.001), representing a mean difference of 3.1 percentage points (95% CI 3.1% to 3.1%). A Cohen d effect size of 0.89 indicated a large effect. At month 5, engaged participants had a mean weight loss of 11.53% (95% CI 11.5% to 11.6%) compared with 8% (95% CI 7.9% to 8%) in the nonengaged participants (P<.001). A Cohen d effect size of 0.56 indicated a moderate effect. Participants using tirzepatide achieved more significant weight loss than those using semaglutide at month 5 (13.9%, 95% CI 13.5% to 14.3% vs 9.5%, 95% CI 9.2% to 9.7%; P<.001). The proportion of engaged participants achieving ≥5%, ≥10%, and ≥15% weight loss was significantly higher than the nonengaged group at corresponding time points from months 3 to 5 respectively (P<.001). Conclusions: Engagement with a digital weight management platform significantly enhances weight loss outcomes among individuals using GLP-1 receptor agonists. The combination of pharmacotherapy and digital behavioral support offers a promising strategy to promote the supported self-care journey of individuals seeking clinically effective obesity management interventions.

Overview

CoChat Summary

TL;DR

In a retrospective service evaluation of 57,975 UK adults using semaglutide or tirzepatide on the Voy digital weight-loss platform, engaged participants lost significantly more weight than nonengaged participants at every time point. Engagement was associated with greater mean weight loss and higher odds of reaching ≥5%, ≥10%, and ≥15% thresholds, but the study is observational and limited by selection bias, self-reported weights, and short follow-up.

Key findings

  • Of 57,975 participants, 31,407 (54.2%) were engaged and 26,568 (45.8%) were nonengaged. At month 3, engaged participants had mean weight loss of 9% (95% CI 9% to 9.1%) versus 5.9% (95% CI 5.9% to 6%) in nonengaged participants (P<.001; difference 3.1 percentage points; Cohen d=0.89). At month 5, engaged participants had mean weight loss of 11.53% (95% CI 11.5% to 11.6%) versus 8% (95% CI 7.9% to 8%) (P<.001; Cohen d=0.56).
  • Participants using tirzepatide achieved greater month 5 weight loss than those using semaglutide: 13.9% (95% CI 13.5% to 14.3%) versus 9.5% (95% CI 9.2% to 9.7%) (P<.001).
  • Engaged participants had significantly higher odds of achieving ≥5% weight loss at all assessed time points, ≥10% from month 2 onward, and ≥15% at months 3 and 4. For example, at month 3 the OR for ≥5% weight loss was 4.01 (95% CI 3.27-4.91; P<.001). Kaplan-Meier analyses showed significant differences; at month 4, 49.3% of engaged participants had not achieved ≥5% weight loss versus 69.8% of nonengaged participants (P<.001).
  • Engagement decreased over time, with 3622 (6.3%) engaged participants remaining at month 5.

Methods

  • Retrospective 2-arm service evaluation using data from the Voy digital health platform between February 2023 and August 2024. Participants were UK adults aged 18-75 years with BMI ≥30 kg/m² or ≥27.5 kg/m² with obesity-related comorbidities who initiated a weight management program involving semaglutide or tirzepatide, with up to 5 months of follow-up.
  • Engagement was the primary exposure, defined as meeting any one of: attended ≥1 weight coaching session, tracked weight ≥1 per week in the app, or logged into the app for features other than only weight logging at least once. Participants were classified as engaged or nonengaged. The primary outcome was percentage weight change from baseline.
  • Analyses included descriptive statistics, chi-square tests (Fisher exact when n<5), independent t tests, Kaplan-Meier survival analysis with log-rank tests, and Cohen d effect sizes. A sensitivity analysis used a subset of 1864 participants with complete baseline data and multivariable linear regression adjusting for age, gender, baseline weight, BMI category, type 2 diabetes, high cholesterol, and high blood pressure. Analyses used R version 4.3.1 with P<.05.

Limitations

  • The paper states potential selection bias because participants who chose to engage may have higher motivation or health literacy; unmeasured confounding; attrition bias from reduced participant numbers over time; missing data on key variables; and self-reported weight measurements that may introduce reporting bias.
  • The paper states the absence of a randomized control group limits causal inference, the 5-month follow-up may not capture long-term weight maintenance, and the predominantly female and White British/Irish population limits generalizability. It also notes the 1864-participant subset may not be representative and that smartphone/tablet access and monthly subscription fees may exclude lower socioeconomic or older adults.
  • Evident from the text: the binary engaged/nonengaged classification collapses variation in engagement intensity, so dose-response relationships are not assessed; the paper acknowledges future tiered analyses could examine low, moderate, or high engagement.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2196/69466

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Flowchart illustrating the critical steps of the retrospective analysis conducted for the Voy digital weight management program. GIP: gastric inhibitory polypeptide; GLP-1: glucagon-like peptide-1.
Figure 1 Flowchart illustrating the critical steps of the retrospective analysis conducted for the Voy digital weight management program. GIP: gastric inhibitory polypeptide; GLP-1: glucagon-like peptide-1.CC BY · PubMed Central
Figure 2 Average weight loss (kg) trajectory over time by engagement status.
Figure 2 Average weight loss (kg) trajectory over time by engagement status.CC BY · PubMed Central
Figure 3 Depicts the mean percentage of weight loss over time by medication type. “All participants” shows the combined weight loss trajectory for both tirzepatide and semaglutide users.
Figure 3 Depicts the mean percentage of weight loss over time by medication type. “All participants” shows the combined weight loss trajectory for both tirzepatide and semaglutide users.CC BY · PubMed Central
Figure 4 Kaplan-Meier survival curves for time to achieve ≥5% weight loss by engagement status. The y‐axis displays the proportion of participants who have not yet reached ≥5% weight loss since baseline. The x‐axis shows time in months from program initiation (ie, when participants began pharmacotherapy and were enrolled in the digital program). The orange line (with shading representing the 95% CI) represents the engaged group, and the blue line (with 95% CI shading) represents the nonengaged group. A log-rank test (χ21=38.39; P<.001) compared the curves over 5 months, revealing a statistically significant difference in the rate at which each group achieved ≥5% weight loss.
Figure 4 Kaplan-Meier survival curves for time to achieve ≥5% weight loss by engagement status. The y‐axis displays the proportion of participants who have not yet reached ≥5% weight loss since baseline. The x‐axis shows time in months from program initiation (ie, when participants began pharmacotherapy and were enrolled in the digital program). The orange line (with shading representing the 95% CI) represents the engaged group, and the blue line (with 95% CI shading) represents the nonengaged group. A log-rank test (χ21=38.39; P<.001) compared the curves over 5 months, revealing a statistically significant difference in the rate at which each group achieved ≥5% weight loss.CC BY · PubMed Central
Figure 5 Kaplan-Meier survival curves for time to achieve ≥10% weight loss by engagement status. The y-axis is the proportion of participants who have not reached ≥10% weight loss, and the x-axis is the time (months) from the program start. The orange line/shading denotes the engaged group; the blue line/shading denotes the nonengaged group. The log-rank test (χ21=45.65; P<.001) indicates a significant difference in time to ≥10% weight loss across the 2 engagement groups.
Figure 5 Kaplan-Meier survival curves for time to achieve ≥10% weight loss by engagement status. The y-axis is the proportion of participants who have not reached ≥10% weight loss, and the x-axis is the time (months) from the program start. The orange line/shading denotes the engaged group; the blue line/shading denotes the nonengaged group. The log-rank test (χ21=45.65; P<.001) indicates a significant difference in time to ≥10% weight loss across the 2 engagement groups.CC BY · PubMed Central
Figure 6 Illustrates the Kaplan-Meier survival curves for time to achieve ≥15% weight loss by engagement status. The y-axis shows the proportion of those who have not achieved ≥15% weight reduction, and the x-axis shows the number of months of follow-up. The orange line/shading denotes the engaged group; the blue line/shading denotes the nonengaged group. The log-rank test (χ21 = 17.72; P<.001) confirms a significant difference in time to ≥15% weight loss between the 2 groups.
Figure 6 Illustrates the Kaplan-Meier survival curves for time to achieve ≥15% weight loss by engagement status. The y-axis shows the proportion of those who have not achieved ≥15% weight reduction, and the x-axis shows the number of months of follow-up. The orange line/shading denotes the engaged group; the blue line/shading denotes the nonengaged group. The log-rank test (χ21 = 17.72; P<.001) confirms a significant difference in time to ≥15% weight loss between the 2 groups.CC BY · PubMed Central

Verification

Claims the paper makes

19 Valid · 1 Not valid · 8 Not checked · 59 Own results and interpretations

30 more claims · 3 with their cited sources checked

Create a free account to see all 87 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 22
  • Probably not a substantial claim. 38
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Research works printed but not linked: 2

  1. El-Osta, A, 2019, SelfCare, 10, 38
  2. Dobbs, R, 2014, Overcoming obesity: an initial economic analysis

Cited by

See all 27

Metadata

Authors
Johnson, H., Huang, D., Liu, V., Ammouri, M. A., Jacobs, C., & El-Osta, A.
Affiliations
  • University of Bristol (GB)
  • Menwell Limited (GB)
  • Imperial College London (GB)
Corresponding author
Johnson, Hans
Venue
Journal of Medical Internet Research
Published
2025-03-31
Volume
27
Pages
e69466
ISSN
1438-8871 (ISSN-L)
OpenAlex
W4408044046
Cited by
27
References
57
Citations by year
2026: 18 · 2025: 9
FWCI
11.34
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Medical Internet Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institute for Health and Care Research
  • Department of Health and Social Care
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
digital health engagement, obesity treatment, weight loss, GLP-1 receptor agonists, semaglutide, tirzepatide, GIP/GLP-1 receptor agonist, mobile health apps, behavioral support, weight monitoring, medication adherence, weight management interventions, obesity-related comorbidities, weight loss outcomes, United Kingdom
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Adolescent, Adult, Aged, Glucagon-Like Peptides, Female, United Kingdom, Humans, Male, Middle Aged, Obesity, Receptors, Gastrointestinal Hormone, Retrospective Studies, Weight Loss, Treatment Outcome, Glucagon-Like Peptide 1, Young Adult, Weight Reduction Programs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.